Can Allianz (XTRA:ALV) Justify Its Valuation After The HSBC Singapore Deal?
Allianz (XTRA:ALV) is back in focus after agreeing to buy HSBC’s Singapore life and health insurance unit for $2.09b, along with a 15-year exclusive bancassurance partnership across the city-state.
See our latest analysis for Allianz.
The HSBC Singapore deal comes at a time when Allianz’s momentum is already positive, with a 30-day share price return of 4.11% and a 90-day share price return of 10.82%, alongside a 5-year total shareholder return of 185.20%.
If this kind of corporate activity has your attention, it can be a good moment to see what else is moving and uncover 107 top founder-led companies
Allianz shares have been climbing as this HSBC Singapore deal lands, which raises a simple tension. Are investors paying up for a stronger underlying insurance and asset management business, or has sentiment just swung ahead of fundamentals?
Most Popular Narrative: 4.2% Overvalued
The most followed Allianz narrative puts fair value at €413.90, compared with a last close of €431.10. This points to a modest valuation premium that hinges on specific growth and margin assumptions.
The analysts have a consensus price target of €413.9 for Allianz based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €684.0, and the most bearish reporting a price target of just €325.0.
Want to see what is built into that fair value for Allianz? Revenue expansion, slimmer margins, and a higher future earnings multiple are all central to this narrative. The key point is how these elements are combined and discounted to today’s price.
Result: Fair Value of €413.90 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Allianz still faces currency volatility and integration risks around acquisitions, which could quickly challenge the assumptions behind this overvalued narrative.
Find out about the key risks to this Allianz narrative.
Another View: Allianz Through a Cash Flow Lens
The analyst narrative has Allianz trading about 4.2% above its €413.90 fair value estimate, which frames the stock as modestly overvalued. Our DCF model points in a very different direction. It values Allianz at €931.84 per share, which is far above the current €431.10 price and implies a large margin between price and estimated future cash flow value.
This split between a relatively cautious analyst fair value and a far higher SWS DCF model outcome highlights how different assumptions about growth, profitability and discount rates can lead to opposite conclusions on Allianz. As an investor, which set of assumptions feels more realistic to you, and how much weight should a long term cash flow view really carry in your process?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Allianz for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 248 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this Allianz story feels finely balanced, it is a good time to move quickly, review the details carefully, and form your own view based on the 4 key rewards.
Looking for more investment ideas beyond Allianz?
Once you have a view on Allianz, do not stop there. Use the screener to compare other opportunities, stress test your convictions, and sharpen your watchlist.
- Target resilient income by reviewing 436 dividend fortresses that aim to combine higher yields with balance sheet strength.
- Hunt for potential mispricing with screener containing 521 high quality undiscovered gems that might not yet sit on most investors’ radar.
- Prioritise capital preservation through 309 resilient stocks with low risk scores that score well on risk metrics and financial robustness.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com